The potential use of service-oriented infrastructure framework to enable transparent vertical scalability of cloud computing infrastructure

Cloud computing technology has become familiar to most Internet users. Subsequently, there has been an increased growth in the use of cloud computing, including Infrastructure as a Service (IaaS). To ensure that IaaS can easily meet the growing demand, IaaS providers usually increase the capacity of their facilities in a vertical IaaS increase capability and the capacity for local IaaS amenities such as increasing the number of servers, storage and network bandwidth. However, at the same time, horizontal scalability is sometimes not enough and requires additional strategies to ensure that the large number of IaaS service requests can be met. Therefore, strategies requiring horizontal scalability are more complex than the vertical scalability strategies because they involve the interaction of more than one facility at different service centers. To reduce the complexity of the implementation of the horizontal scalability of the IaaS infrastructures, the use of a technology service oriented infrastructure is recommended to ensure that the interaction between two or more different service centers can be done more simply and easily even though it is likely to involve a wide range of communication technologies and different cloud computing management. This is because the service oriented infrastructure acts as a middle man that translates and processes interactions and protocols of different cloud computing infrastructures without the modification of the complex to ensure horizontal scalability can be run easily and smoothly. This paper presents the potential of using a service-oriented infrastructure framework to enable transparent vertical scalability of cloud computing infrastructures by adapting three projects in this research: SLA@SOI consortium, Open Cloud Computing Interface (OCCI), and OpenStack

Islamisation of engineering education – a case at IIUM

Seeking knowledge and continuing education are very important elements in Islam. All Muslims (both male and female) are required to make sincere efforts to acquire knowledge for the benefits of themself and the society; They believe that there is only one God (Allah) and He is the ultimate source of all knowledge. Although the education system has various branches, this paper is intended to present the common issues related to the Islamic values and practices in engineering education and the ways to instil ethics & spirituality into the technical education system. The step by step initiatives taken by the faculty of engineering at the International Islamic University Malaysia (IIUM) is highlighted in this paper. In order to achieve the goals of Islamisation of engineering education at IIUM, the relevant Islamic elements are added into the curriculums, textbooks are written and learning outcomes are set (at IIUM) to assess the student’s ability in appreciating the link between the revealed and acquired knowledge. Generally, such initiatives are welcomed by the students, though it requires a substantial amount of continuous efforts from the academic staffs. It is realised that Islamisation of the engineering education and continuous reminder of spirituality in engineering practices are essential to reduce the corruption and unethical practices in the engineering profession, which is one of the major socio-economic problems in many countries, rich or poor, developed or developing. Steps taken in the engineering curriculum design is part of the faculty’s initiatives to achieve its vision, which is to be a world-class centre for engineering education and research with values and ethics. Information shared in this paper could be beneficial for both secular and non-secular education system

Global economic burden of unmet surgical need for appendicitis

Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was USD 92 492 million using approach 1 and USD 73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was USD 95 004 million using approach 1 and USD 75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially.publishedVersio

BIM-driven energy simulation and optimization for net-zero tall buildings: sustainable construction management

The growing demand for sustainable and energy-efficient buildings, particularly in the context of tall structures, has prompted increased attention to innovative solutions. Despite advancements in Building Information Modelling (BIM) technology, there exists a critical gap in understanding its comprehensive application for achieving net-zero energy consumption in tall buildings, particularly in the Malaysian construction industry. This research addresses this gap by presenting a novel strategy that integrates BIM technology with energy analysis tools for net-zero tall buildings in Malaysia. The aim of the study is to contribute valuable insights to the construction industry, policymakers, and researchers by conducting empirical research, utilizing case studies, validating the proposed framework, advancing sustainable design practices, and supporting the transition towards net-zero energy tall buildings in Malaysia. The methodology involves a three-phase approach, including qualitative analysis, a pilot survey, and a main questionnaire. Exploratory factor analysis (EFA) validates the categorization derived from qualitative interviews, while Partial Least Squares Structural Equation Modelling (PLS-SEM) assesses the convergent and discriminant validity of the measurement model. Hypotheses testing using bootstrapping establishes the significance of correlations between BIM deployment and key factors such as early design integration, enhanced energy efficiency, optimized system integration, predictive performance analysis, and validation of sustainable design. The research findings support the positive associations between BIM deployment and the mentioned factors, providing statistical significance through T-statistics and p-values. The implications of this research extend beyond the Malaysian context, offering valuable insights for architects, engineers, and stakeholders involved in designing and managing sustainable tall buildings. By addressing the identified gaps and leveraging BIM technology effectively, stakeholders can contribute to the construction of net-zero energy structures, aligning with global efforts towards sustainable and energy-efficient building practices

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was done, which included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) and is ongoing. Findings: Between Feb 2 and Dec 29, 2021, from 10 852 enrolled, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% were receiving tocilizumab (with planned use within the next 24 h recorded for a further 9%). Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77–0·99; p=0·028). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of eight previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths), in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0·57; 95% CI 0·45–0·72). Including the results from RECOVERY in an updated meta-analysis of all nine completed trials (involving 11 888 randomly assigned patients and 1485 deaths) allocation to baricitinib or another JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0·80; 95% CI 0·72–0·89; p<0·0001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no significant excess of thrombosis, or other safety outcomes. Interpretation: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Islamic leadership and maqasid al-shari'ah: Reinvestigating the dimensions of Islamic leadership inventroy (ILI) via content analysis procedures

The purpose of this research is to investigate separate themes of Islamic Leadership based on analyses conducted on selected literature of conventional and Islamic Leadership.The themes of Islamic Leadership were identified for the purpose of developing a specific inventory to measure Islamic Leadership or the Islamic Leadership Inventory (ILI).In identifying the themes of Islamic Leadership, this research applied qualitative content analysis procedures on four categories of literature.The literature are (1) The Qur’an and Hadiths (2) Managerial Leadership and Servant Leadership literature (3) Contemporary Islamic Leadership literature (4) Classical texts of Islamic Leadership.This research used NVIVO to facilitate information processing.With respect to the underlying theory of research, this research is based on the principles of higher objectives of Shari’ah or the Maqasid al-Shari’ah to justify the importance of the identified Islamic Leadership behaviors from the lenses of Islam. Based on the content analysis, this research found 25 separate themes representing Islamic Leadership Behaviours.The 25 themes are (1) Trustworthiness and Integrity, (2) Employees Orientation, (3) Self-evaluation, (4) Patience, (5) Outcome Orientation, (6) Empowerment, (7) Social Responsibility (8) Flexibility (9) Non Calculative, (10) Spirituality, Religiousness and Piety, (11) Esprit De Corps, (12) Bravery, (13) Justice and Equity, (14) High Self-Reliance and High SelfEsteem, (15) Modesty and Shyness, (16) Impartially, (17) Moderation and Balance, (18) Good in Communication, (19) Free from environmental-constrains, (20) Earnest, (21) Cheerful, (22) Feared when angry, (23) Empowering Intelligent, Wisdom and Encourage Synergy, (24) Role Model, and (25) Avoid Conflict.The themes suggested could be used to measure Islamic Leadership in various perspectives.In general, this paper offers policymakers, organisations, and researchers in various avenues the important dimensions of Islamic Leadership.Specifically, the Islamic Leadership Inventory (ILI) could be utilised to measure the effectiveness of Muslims’ professionals based on the perspectives of Islam and the higher objectives of Shari’ah.In sum, this paper found that Islamic Leadership could be represented in several dimensions and could be adapted in the conventional measures of managerial leadership

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0·79, 95% CI 0·69–0·91; p=0·0009). In an analysis of all randomly assigned patients (regardless of baseline antibody status), 943 (19%) of 4839 patients allocated to casirivimab and imdevimab versus 1029 (21%) of 4946 patients allocated to usual care died within 28 days (RR 0·94, 95% CI 0·86–1·02; p=0·14). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0·002). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab. Interpretation: In patients admitted to hospital with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab reduced 28-day mortality in patients who were seronegative (and therefore had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research